News Release

Insilico Medicine and National Laboratory Astana to develop human aging biomarkers

Insilico Medicine and National Laboratory Astana, Nazarbayev University to develop integrated biomarkers of human aging

Business Announcement

InSilico Medicine

InSilico Medicine

image: Insilico Medicine logo. view more 

Credit: Insilico Medicine

Astana, May 18th, 2016. Insilico Medicine announced an agreement with National Laboratory Astana, Nazarbayev University, one of the most rapidly growing universities in the world to collaboratively study aging and age-associated pathologies.

"We are very happy to collaborate with Insilico Medicine, one of the leaders in applying artificial intelligence to aging research. At the Nazarbayev University we are generating vast amounts of data, including next generation sequencing, gut microbiome, genomic and metabolomic data. Healthy aging and healthspan extension is one of our main research priorities. Deep learning has revolutionized many areas including image and text recognition and is likely to advance many areas of biomedicine," said Zhaxybay Zhumadilov, General Director of the National Laboratory Astana, Nazarbayev University.

In the scope of the agreement, Insilico Medicine will provide advanced signaling pathway activation analysis services to evaluate differential changes between healthy tissues and those affected by disease as well as comparing tissues of different ages. In addition to signaling pathway analysis, parties intend to develop artificially-intelligent comprehensive biomarkers of human aging based on large sample data sets.

"Nazarbayev University is one of the most advanced universities in Eastern Europe and Central Asia with state of the art equipment and highly qualified staff educated in top international universities. This institution is scouting for cutting-edge technologies and Insilico Medicine is delighted to be selected as one of the providers of high-technology solutions for longevity research," said Alex Zhavoronkov, CEO of Insilico Medicine. Inc, who was one of the speakers of the recently past the IV International conference on regenerative medicine and healthy aging, held at the National Laboratory Astana on 11-12 May, 2016.


About Insilico Medicine

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video:

About National Laboratory Astana

National Laboratory Astana at Nazarbayev University includes Center for Life Sciences, Interdisciplinary Instrumental Center and Center for Energy Research. The main goals of the institution is carrying out multidisciplinary basic and/or applied research in the field of life sciences, energy, and other interdisciplinary areas of science, as well as activities to establish a scientific laboratory, experimental bases, centers, institutes for the development and implementation of scientific, scientific and technical, educational programs and training.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.